Free Trial

5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
AbbVie (ABBV)
4.0524 of 5 stars
$262.47-0.1%2.64%74.12Moderate Buy$272.39
Mondelez International (MDLZ)
4.7426 of 5 stars
$58.01-0.3%3.59%21.33Moderate Buy$66.61
ExxonMobil (XOM)
3.4409 of 5 stars
$163.93-0.1%2.51%21.11Hold$164.78
Schwab US Dividend Equity ETF (SCHD)N/A$32.63-0.3%3.22%14.57Moderate Buy$32.40
NEOS Nasdaq 100 High Income ETF (QQQI)N/A$56.330.4%13.56%32.88Moderate Buy$56.32

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines